Recombinant Human TNFSF14
Cat.No. : | TNFSF14-29950TH |
Product Overview : | Recombinant fragment, corresponding to amino acids 64-240 of Human LIGHT produced in Insect cells; 177 amino acids, 19.3kDa. |
- Specification
- Gene Information
- Related Products
Description : | The protein encoded by this gene is a member of the tumor necrosis factor (TNF) ligand family. This protein is a ligand for TNFRSF14, which is a member of the tumor necrosis factor receptor superfamily, and which is also known as a herpesvirus entry mediator (HVEM). This protein may function as a costimulatory factor for the activation of lymphoid cells and as a deterrent to infection by herpesvirus. This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. This protein is also reported to prevent tumor necrosis factor alpha mediated apoptosis in primary hepatocyte. Two alternatively spliced transcript variant encoding distinct isoforms have been reported. |
Tissue specificity : | Predominantly expressed in the spleen but also found in the brain. Weakly expressed in peripheral lymphoid tissues and in heart, placenta, liver, lung, appendix, and kidney, and no expression seen in fetal tissues, endocrine glands, or nonhematopoietic tu |
Form : | Lyophilised:Reconstituted LIGHT is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. Avoid repeated freeze/thaw cycles. |
Purity : | >95% by SDS-PAGE |
Storage : | Store at -20°C. Stable for 12 months at -20°C |
Sequences of amino acids : | RLGEMVTRLP DGPAGSWEQL IQERRSHEVN PAAHLTGANS SLTGSGGPLL WETQLGLAFL RGLSYHDGAL VVTKAGYYYI YSKVQLGGVG CPLGLASTIT HGLYKRTPRY PEELELLVSQ QSPCGRATSS SRVWWDSSFL GGVVHLEAGE KVVVRVLDER LVRLRDGTRS YFGAFMV |
Sequence Similarities : | Belongs to the tumor necrosis factor family. |
Gene Name : | TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ] |
Official Symbol : | TNFSF14 |
Synonyms : | TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; |
Gene ID : | 8740 |
mRNA Refseq : | NM_003807 |
Protein Refseq : | NP_003798 |
MIM : | 604520 |
Uniprot ID : | O43557 |
Chromosome Location : | 19p13.3 |
Pathway : | Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Herpes simplex infection, organism-specific biosystem; Herpes simplex infection, conserved biosystem; |
Function : | cysteine-type endopeptidase inhibitor activity involved in apoptotic process; cytokine activity; protein binding; receptor binding; tumor necrosis factor receptor binding; |
Products Types
◆ Recombinant Protein | ||
TNFSF14-4501H | Recombinant Human TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
TNFSF14-1544M | Recombinant Mouse TNFSF14 Protein, His-tagged | +Inquiry |
TNFSF14-288H | Recombinant Human TNFSF14 Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
Tnfsf14-6555M | Recombinant Mouse Tnfsf14 Protein, Myc/DDK-tagged | +Inquiry |
TNFSF14-150H | Recombinant Human TNFSF14 Protein, His-tagged | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket